These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 11034810)

  • 1. Pre-clinical evaluation of the activity of gemcitabine as a basis for regional chemotherapy of pancreatic and colorectal cancer.
    Kornmann M; Butzer U; Blatter J; Beger HG; Link KH
    Eur J Surg Oncol; 2000 Sep; 26(6):583-7. PubMed ID: 11034810
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pre-clinical evaluation of the activity of irinotecan as a basis for regional chemotherapy.
    Hofmann C; Buttenschoen K; Straeter J; Henne-Bruns D; Kornmann M
    Anticancer Res; 2005; 25(2A):795-804. PubMed ID: 15868911
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Oxaliplatin exerts potent in vitro cytotoxicity in colorectal and pancreatic cancer cell lines and liver metastases.
    Kornmann M; Fakler H; Butzer U; Beger HG; Link KH
    Anticancer Res; 2000; 20(5A):3259-64. PubMed ID: 11062751
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Chemosensitization and inhibition of pancreatic cancer stem cell proliferation by overexpression of microRNA-205.
    Chaudhary AK; Mondal G; Kumar V; Kattel K; Mahato RI
    Cancer Lett; 2017 Aug; 402():1-8. PubMed ID: 28536008
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antiangiogenic versus cytotoxic therapeutic approaches to human pancreas cancer: an experimental study with a vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor and gemcitabine.
    Bocci G; Danesi R; Marangoni G; Fioravanti A; Boggi U; Esposito I; Fasciani A; Boschi E; Campani D; Bevilacqua G; Mosca F; Del Tacca M
    Eur J Pharmacol; 2004 Sep; 498(1-3):9-18. PubMed ID: 15363970
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase I/II Trial of Anticarcinoembryonic Antigen Radioimmunotherapy, Gemcitabine, and Hepatic Arterial Infusion of Fluorodeoxyuridine Postresection of Liver Metastasis for Colorectal Carcinoma.
    Cahan B; Leong L; Wagman L; Yamauchi D; Shibata S; Wilzcynski S; Williams LE; Yazaki P; Colcher D; Frankel P; Wu A; Raubitschek A; Shively J; Wong JYC
    Cancer Biother Radiopharm; 2017 Sep; 32(7):258-265. PubMed ID: 28910150
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [A case of postoperative multiple liver metastases of pancreatic cancer successfully treated by combination chemotherapy with weekly high-dose 5-FU hepatic arterial infusion plus systemic infusion of gemcitabine].
    Doh J; Sho M; Tanaka T; Yamada T; Nomi T; Akahori T; Yamato I; Nishiofuku H; Tamamoto T; Hasegawa M; Kichikawa K; Nakajima Y
    Gan To Kagaku Ryoho; 2009 Nov; 36(12):2087-9. PubMed ID: 20037332
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Berberine diminishes side population and down-regulates stem cell-associated genes in the pancreatic cancer cell lines PANC-1 and MIA PaCa-2.
    Park SH; Sung JH; Chung N
    Mol Cell Biochem; 2014 Sep; 394(1-2):209-15. PubMed ID: 24894821
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Synergistic cytotoxicity and pharmacogenetics of gemcitabine and pemetrexed combination in pancreatic cancer cell lines.
    Giovannetti E; Mey V; Danesi R; Mosca I; Del Tacca M
    Clin Cancer Res; 2004 May; 10(9):2936-43. PubMed ID: 15131028
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [A case of liver metastasis of pancreatic cancer that was resistant to S-1 and gemcitabine successfully treated by 5-FU and cisplatin hepatic arterial infusion].
    Iwauchi T; Amano R; Ohira G; Nakamoto K; Doi Y; Yamada N; Ohira M; Hirakawa K
    Gan To Kagaku Ryoho; 2010 Nov; 37(12):2373-5. PubMed ID: 21224577
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Hepatic arterial infusion chemotherapy with gemcitabine for patients with postoperative liver metastases from pancreatic cancer].
    Tajima H; Kitagawa H; Shoji M; Okamoto K; Nakanuma S; Sakai S; Kinoshita J; Makino I; Hayashi H; Nakamura K; Oyama K; Nakagawara H; Miyashita T; Takamura H; Ohta T; Minami T; Koda W; Sanada J; Gabata T; Sai Y
    Gan To Kagaku Ryoho; 2013 Nov; 40(12):1668-71. PubMed ID: 24393883
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment with gemcitabine and TRA-8 anti-death receptor-5 mAb reduces pancreatic adenocarcinoma cell viability in vitro and growth in vivo.
    DeRosier LC; Huang ZQ; Sellers JC; Buchsbaum DJ; Vickers SM
    J Gastrointest Surg; 2006 Nov; 10(9):1291-300; discussion 1300. PubMed ID: 17114015
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [In vitro evaluation of potentially effective gemcitabine combination therapy for exocrine pancreatic carcinoma].
    Kreil A; Bauer J; Scheithauer W
    Acta Med Austriaca; 1999; 26(3):93-100. PubMed ID: 10520377
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Synergistic effects of deuterium oxide and gemcitabine in human pancreatic cancer cell lines.
    Bader Y; Hartmann J; Horvath Z; Saiko P; Grusch M; Madlener S; Maier S; Oehler L; Fritzer-Szekeres M; Heller N; Alken RG; Krupitza G; Szekeres T
    Cancer Lett; 2008 Feb; 259(2):231-9. PubMed ID: 18023527
    [TBL] [Abstract][Full Text] [Related]  

  • 15. MiR-608 regulating the expression of ribonucleotide reductase M1 and cytidine deaminase is repressed through induced gemcitabine chemoresistance in pancreatic cancer cells.
    Rajabpour A; Afgar A; Mahmoodzadeh H; Radfar JE; Rajaei F; Teimoori-Toolabi L
    Cancer Chemother Pharmacol; 2017 Oct; 80(4):765-775. PubMed ID: 28887583
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nuclear factor-kappaB p65/relA silencing induces apoptosis and increases gemcitabine effectiveness in a subset of pancreatic cancer cells.
    Pan X; Arumugam T; Yamamoto T; Levin PA; Ramachandran V; Ji B; Lopez-Berestein G; Vivas-Mejia PE; Sood AK; McConkey DJ; Logsdon CD
    Clin Cancer Res; 2008 Dec; 14(24):8143-51. PubMed ID: 19088029
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mechanisms underlying gemcitabine resistance in pancreatic cancer and sensitisation by the iMiD™ lenalidomide.
    Fryer RA; Barlett B; Galustian C; Dalgleish AG
    Anticancer Res; 2011 Nov; 31(11):3747-56. PubMed ID: 22110196
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Transferrin receptor targeting nanomedicine delivering wild-type p53 gene sensitizes pancreatic cancer to gemcitabine therapy.
    Camp ER; Wang C; Little EC; Watson PM; Pirollo KF; Rait A; Cole DJ; Chang EH; Watson DK
    Cancer Gene Ther; 2013 Apr; 20(4):222-8. PubMed ID: 23470564
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Repeated hepatic intra-arterial chemotherapy based on results of anticancer drug sensitivity test in patients with synchronous hepatic metastases from colorectal cancer.
    Matsuoka H; Nagaya M; Tsukikawa S; Yanagi Y; Isogai A; Kubota S
    Surgery; 2006 Sep; 140(3):387-95. PubMed ID: 16934600
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dose-escalating study of capecitabine plus gemcitabine combination therapy in patients with advanced cancer.
    Schilsky RL; Bertucci D; Vogelzang NJ; Kindler HL; Ratain MJ
    J Clin Oncol; 2002 Jan; 20(2):582-7. PubMed ID: 11786589
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.